Sai Life Sciences Q1 FY27 earnings call transcript filed
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences reported Q1 FY27 revenue of INR553 crore, up 12% YoY. CRO grew 26% while CDMO grew 6%. Management maintained 15-20% revenue growth and 28-30% EBITDA guidance over the mid-term. FY27 capex guided at INR1,100-1,300 crore. CMC pipeline has 33 active commercial and 14 late-phase molecules, with 6 late-phase additions in 15 months. Repeat customers contributed over 90% of revenue. Stronger H2 expected as capacity goes live. Peptide manufacturing facility planned for 2028. EcoVadis Platinum rating secured.
Steady growth and reaffirmed guidance signal operational stability; H2 capacity ramp could drive upside. Peptide expansion adds long-term optionality.